This is a non-core endpoint: only basic statistics are computed.
Malignant neoplasm of other and ill-defined sites
C3_OTHER_OR_ILLDEFINED_SITES
benign neoplasm: A neoplasm which is characterized by the absence of morphologic features associated with malignancy (severe cytologic atypia, tumor cell necrosis, and high mitotic rate). Benign neoplasms remain confined to the original site of growth and do not metastasize to other anatomic sites.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
557745 |
1. Apply sex-specific ruleNone |
557745 |
2. Check conditionsNone |
557745 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
139 |
4. Check minimum number of eventsNone |
139 |
5. Include endpointsNone |
139 |
6. Filter based on genotype QC (FinnGen only) |
127 |
Control definitions (FinnGen only)
- Control exclude
- C3_CANCER, C3_CANCER_WIDE
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF9
Similar endpoints
↥List of similar endpoints to
Malignant neoplasm of other and ill-defined sites
based on the number of shared cases.
Similar with more cases:
- Malignant neoplasm of other and ill-defined sites, including Hilmo
- Secondary uncertain malignant neoplasm
- Solid cancers
- Malignant neoplasm
- Malignant neoplasm
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
This endpoint is excluded from FinRegistry analyses (omitted endpoint).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 127 | 42 | 85 |
| Unadjusted period prevalence (%) | 0.03 | 0.01 | 0.04 |
| Median age at first event (years) | 74.53 | 78.40 | 72.61 |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
Not a core endpoint, no data to show.
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 128
- Matched controls
- 1280
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
C76.2
ICD-10 Finland
Malignant neoplasm of other and ill-defined sites: Abdomen
+∞
60.3
53
*
130
Kela drug reimbursment
Malignant tumour
+∞
38.5
35
*
Z51.5
ICD-10 Finland
Palliative care
12.6
28.9
32
33
8000/3-C76.2
ICD-O-3
Neoplasm, malignant of abdomen, NOS
+∞
22.6
21
*
A03FA01
ATC
metoclopramide; systemic, rectal
6.8
20.6
40
80
H02AB02
ATC
dexamethasone; systemic
58.7
17.6
20
*
C78.7
ICD-10 Finland
Secondary malignant neoplasm of liver and intrahepatic bile duct
+∞
16.0
15
*
8000/3-C80.9
ICD-O-3
Neoplasm, malignant of unknown primary site
+∞
13.8
13
*
8140/3-C76.2
ICD-O-3
Adenocarcinoma, NOS, of abdomen, NOS
+∞
11.6
11
*
C76.3
ICD-10 Finland
Malignant neoplasm of other and ill-defined sites: Pelvis
+∞
10.6
10
*
C76.0
ICD-10 Finland
Malignant neoplasm of other and ill-defined sites: Head, face and neck
+∞
10.6
10
*
C76.1
ICD-10 Finland
Malignant neoplasm of other and ill-defined sites: Thorax
+∞
10.6
10
*
C61
ICD-10 Finland
Malignant neoplasm of prostate
+∞
10.6
10
*
C78.6
ICD-10 Finland
Secondary malignant neoplasm of retroperitoneum and peritoneum
+∞
10.6
10
*
8140/3-C61.9
ICD-O-3
Adenocarcinoma, NOS, of prostate gland
+∞
9.5
9
*
C79.8
ICD-10 Finland
Secondary malignant neoplasm of other specified sites
+∞
9.5
9
*
L01BC06
ATC
capecitabine; oral
+∞
8.4
8
*
C80
ICD-10 Finland
Malignant neoplasm, without specification of site
+∞
8.4
8
*
N02AB03
ATC
fentanyl; nasal, sublingual, transdermal
10.4
8.0
15
16
C44.31
ICD-10 Finland
Basocellular carcinoma of the skin on another or unspecified part of the face
+∞
7.4
7
*
A04AA02
ATC
granisetron; systemic, transdermal
+∞
7.4
7
*
WD125
NOMESCO Finland
Demanding cystostatic therapy of methastized malignancy
+∞
7.4
7
*
8140/3-C80.9
ICD-O-3
Adenocarcinoma, NOS, of unknown primary site
+∞
7.4
7
*
JN4AD
NOMESCO Finland
Body CT examination
7.2
6.9
16
25
JN4BD
NOMESCO Finland
Extensive body CT
6.6
6.9
17
29
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
2.7
6.6
48
230
N02AA05
ATC
oxycodone; systemic
3.0
6.5
35
143
WF049
NOMESCO Finland
Radiotherapy of metastasis
73.4
6.5
7
*
R18
ICD-10 Finland
Ascites
19.2
6.4
9
5
QAE10
NOMESCO Finland
Excision of other lesion extending through all layers of skin in head or neck
8.4
6.3
13
17
8090/3-C44.9
ICD-O-3
Basal cell carcinoma, NOS, of skin, NOS
+∞
6.3
6
*
C80.90
ICD-10 Finland
Malignant tumor without specified localization without histology
+∞
6.3
6
*
C26.9
ICD-10 Finland
Malignant neoplasm: Ill-defined sites within the digestive system
+∞
6.3
6
*
8000/3-C76.1
ICD-O-3
Neoplasm, malignant of thorax, NOS
+∞
6.3
6
*
8070/3-C80.9
ICD-O-3
Squamous cell carcinoma, NOS, of unknown primary site
+∞
6.3
6
*
A04AA01
ATC
ondansetron; systemic, rectal
10.8
6.2
11
11
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
9
0
+∞
9.49
1.6
0.0
26.98
—
ug/l
—
9
0
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
15
26
6.39
6.05
1.9
2.3
0.23
0.32
iu/ml
—
8
11
14
51
2.96
3.10
9.4
7.8
23.55
24.16
mmol/l
0.17
14
51
8
17
4.94
2.97
1.3
2.4
79.88
82.24
%
—
8
17
7
14
5.22
2.77
1.1
1.1
—
—
—
0
0
42
603
0.55
2.57
41.1
23.4
328.14
331.15
g/l
1.63
42
595
31
184
1.90
2.32
3.4
2.0
—
—
—
0
0
8
24
3.48
2.22
1.3
1.3
—
—
—
0
0
15
70
2.29
2.08
1.5
1.7
—
—
—
0
0
6
15
4.14
2.06
1.0
1.3
0.28
0.20
g/l
—
6
15
6
15
4.14
2.06
1.0
1.5
1.36
0.98
g/l
—
6
15
58
429
1.64
2.00
9.2
3.6
15.87
12.94
umol/l
0.52
58
402
6
16
3.88
1.96
1.2
1.8
249.00
79.97
u/ml
—
6
16
55
702
0.62
1.88
6.7
7.5
41.04
41.72
mmol/mol
0.22
49
638
13
61
2.26
1.78
1.5
1.6
—
—
—
0
0
5
14
3.67
1.63
1.2
1.9
—
—
—
0
0
57
709
0.65
1.62
29.7
17.7
69.55
68.11
ml/min/173m2
0.19
57
653
46
592
0.65
1.49
34.5
22.3
14.68
13.94
%
3.42
46
575
7
28
2.58
1.47
2.1
4.4
—
—
—
0
0
57
700
0.67
1.45
4.3
5.4
4.25
4.25
mmol/l
0.01
50
622
5
16
3.21
1.45
1.4
1.3
—
—
—
0
0
60
726
0.67
1.39
5.1
5.6
6.10
6.23
mmol/l
0.31
51
627
54
420
1.49
1.39
9.8
5.0
4.45
4.73
e9/l
0.35
43
354
60
725
0.68
1.37
4.7
6.2
2.45
2.40
mmol/l
0.19
50
636
5
17
3.02
1.37
1.2
1.3
—
—
—
0
0
11
55
2.09
1.31
13.5
8.2
95.22
94.03
%
1.27
11
55
56
445
1.46
1.27
8.5
5.5
1.22
1.20
mmol/l
0.90
50
365
58
696
0.70
1.21
4.4
5.3
1.39
1.42
mmol/l
0.25
50
609
11
57
2.02
1.21
13.5
7.9
0.67
0.67
%
0.00
11
57
8
38
2.18
1.21
1.1
1.3
—
—
—
0
0
28
195
1.56
1.18
2.2
2.5
359.52
381.21
umol/l
0.47
21
159
45
349
1.45
1.14
2.6
2.8
219.48
129.02
ug/l
1.60
39
309
55
661
0.71
1.12
4.1
4.6
1.16
1.25
mmol/l
0.65
46
569
11
59
1.95
1.11
13.5
7.8
1.10
1.29
%
0.52
11
59
43
333
1.44
1.09
3.5
2.4
—
—
estimate
—
0
0
21
143
1.56
0.97
3.7
2.8
1.16
1.55
e6/l
—
9
77
33
252
1.42
0.89
3.6
3.0
0.53
0.60
e6/l
0.13
23
194
19
130
1.54
0.87
1.9
1.8
—
—
—
0
0
25
183
1.45
0.84
2.0
1.8
—
—
—
0
0
35
273
1.39
0.84
2.0
2.4
3.01
2.89
mg/l
0.13
28
223
20
140
1.51
0.83
3.8
3.0
2.61
2.44
e6/l
—
8
71
39
312
1.36
0.80
4.4
3.3
—
—
—
0
0
10
59
1.75
0.78
1.8
3.5
23.48
23.11
mmol/l
—
10
59
19
261
0.68
0.78
5.2
3.9
22.04
26.88
%
—
10
134
18
127
1.49
0.73
4.2
4.2
1.14
1.05
mmol/l
0.41
18
110
7
40
1.79
0.72
1.3
1.4
—
—
—
0
0
61
691
0.78
0.69
5.5
5.2
1.99
2.09
mu/l
0.23
55
591
5
27
1.89
0.69
4.0
1.3
40.94
41.24
u/l
—
5
21
19
141
1.41
0.61
1.9
1.7
—
—
—
0
0
29
234
1.31
0.56
2.3
1.9
610.21
452.10
pmol/l
0.65
24
191
28
341
0.77
0.54
5.7
4.4
0.00
0.00
estimate
—
10
68
37
434
0.79
0.53
5.1
4.2
0.00
0.00
estimate
-0.00
11
92
9
64
1.44
0.53
1.7
1.6
—
—
—
0
0
38
442
0.80
0.50
2.3
2.3
106.07
89.23
pmol/l
0.78
24
229
21
263
0.76
0.50
5.0
4.4
0.00
0.00
estimate
—
9
87
17
129
1.37
0.49
11.4
5.3
103.88
104.41
mmol/l
0.15
17
129
38
439
0.81
0.47
4.8
4.3
0.00
0.00
estimate
-0.00
11
92
16
122
1.36
0.45
10.9
5.5
4.95
5.04
kpa
0.15
16
117
16
122
1.36
0.45
10.9
5.5
12.60
11.03
kpa
0.91
16
117
38
437
0.81
0.45
5.0
4.2
0.00
0.00
estimate
-0.00
11
97
8
55
1.48
0.44
2.6
2.4
1.35
1.02
%
—
8
55
6
42
1.45
0.36
1.7
1.5
—
—
—
0
0
6
45
1.35
0.34
1.7
1.7
—
—
—
0
0
7
52
1.37
0.32
1.6
1.4
—
—
—
0
0
13
102
1.31
0.31
4.1
4.0
—
—
—
0
0
26
226
1.19
0.27
2.2
1.8
1312.44
1156.26
nmol/l
0.26
20
166
21
242
0.84
0.25
5.3
3.8
0.20
0.00
estimate
—
10
71
33
363
0.88
0.22
2.0
2.4
—
—
—
0
0
0
10
0.00
0.21
0.0
1.4
—
—
—
0
0
0
10
0.00
0.21
0.0
1.5
—
—
—
0
0
53
565
0.89
0.21
4.2
3.9
15.04
15.16
pmol/l
0.13
48
487
0
13
0.00
0.21
0.0
1.6
—
—
—
0
0
0
14
0.00
0.20
0.0
1.4
—
—
—
0
0
33
354
0.91
0.14
2.2
2.4
73.63
80.51
nmol/l
0.67
27
299
5
45
1.12
0.10
2.0
1.2
10.76
10.72
g/l
—
5
37
6
57
1.06
0.08
3.3
2.9
24.55
24.80
mmol/l
—
6
52
8
74
1.09
0.07
4.0
3.2
75.63
92.28
ng/l
—
8
61
30
315
0.94
0.07
4.3
3.7
16.30
6.25
mg/mmol
0.50
21
208
58
594
0.96
0.05
4.8
4.0
24.28
16.20
mm/h
1.88
53
527
30
290
1.05
0.03
4.9
2.1
2.32
2.35
mmol/l
0.41
30
245
21
206
1.02
0.00
5.0
2.5
2.48
2.45
mmol/l
0.54
21
175
0
5
0.00
0.00
0.0
2.2
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
0.78
—
0
5
0
5
0.00
0.00
0.0
1.4
—
—
—
0
0
9
98
0.91
-0.00
4.9
9.1
—
—
—
0
0
5
58
0.86
-0.00
1.0
1.7
1.38
1.68
%
—
5
50
0
7
0.00
-0.00
0.0
2.3
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
7
0.00
-0.00
0.0
3.1
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
5
50
1.00
-0.00
2.0
1.3
3.50
3.62
g/l
—
5
42
5
50
1.00
-0.00
2.0
1.3
4.00
4.14
g/l
—
5
42
8
84
0.95
-0.00
2.0
2.4
0.31
0.39
e6/l
—
8
79
0
8
0.00
-0.00
0.0
1.4
—
—
—
0
0
5
50
1.00
-0.00
2.0
1.3
8.00
7.82
g/l
—
5
42
Mortality – FinRegistry
↥This endpoint is excluded from FinRegistry analyses (omitted endpoint).
Relationships between endpoints
↥Index endpoint: C3_OTHER_OR_ILLDEFINED_SITES – Malignant neoplasm of other and ill-defined sites
GWS hits: -
This endpoint is excluded from FinRegistry analyses (omitted endpoint).